ArticleCancer cell international2022

HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53.

Tiebo Mao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.